ImCheck Therapeutics
Latest round
- Series C
Last raised
- Sep 2022
Total raised
- $131M
Investors
- 15
About ImCheck Therapeutics
ImCheck Therapeutics SAS, established in 2015 in Marseille, France, specializes in the development of immunotherapeutic products. Pierre d'Epenoux serving as the CEO. In October 2025, Ipsen Group agreed to fully acquire ImCheck Therapeutics SAS from Kinled Holding, Boehringer Ingelheim Venture, Eurazeo, Kurma Partners, EQT Life Sciences, Gimv, Bpifrance, Agent Capital, Alexandria Venture Investments, Bpifrance Investissement, Pfizer Venture Investments, Wellington Partners, Pureos Bioventures, Earlybird Venture Capital, Invus [DUP], The Leukemia & Lymphoma Society for an upfront payment of EUR 350 million. The deal is subject to customary closing condition and is expected to be completed on the end of first quarter of 2026.ImCheck Therapeutics specializes in the development of innovative immunotherapeutic antibodies aimed at modulating the immune system through their proprietary knowledge of butyrophilin (BTN) and BTN-like (BTNL) checkpoint molecules.ImCheck Therapeutics generates revenue through strategic partnerships and collaborations centered on their flagship products, notably ICT01, focusing on acute myeloid leukemia (AML). Revenue is derived from milestone payments and royalties based on product candidates' success, structured through agreements that outline specific deliverables and performance metrics.In October 2025, Ipsen Group agreed to fully acquire ImCheck Therapeutics SAS. The company plans to advance its oncology pipeline by integrating ImCheck’s ICT01 antibody program for acute myeloid leukemia into late-stage clinical development.
Who invested in ImCheck Therapeutics
15 investors across 7 rounds
See all investors in ImCheck Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Sep 22, 2022
Amount
$65M
Investors
Series B
Aug 5, 2021
Amount
$19M
Investors
Series B
Aug 24, 2020
Amount
$3M
Investors
Series B
Nov 12, 2019
Amount
$22M
Investors
Series A
Jun 13, 2018
Amount
$14M
Investors
Series A
Jun 20, 2017
Amount
$5.6M
Investors
Series A
Nov 3, 2016
Amount
$2.6M
Investors
Questions about ImCheck Therapeutics
Who invested in ImCheck Therapeutics?
ImCheck Therapeutics has 15 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImCheck Therapeutics raised?
ImCheck Therapeutics has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did ImCheck Therapeutics last raise money?
ImCheck Therapeutics's most recent round on record is a Series C, in Sep 2022.
What does ImCheck Therapeutics do?
ImCheck Therapeutics SAS, established in 2015 in Marseille, France, specializes in the development of immunotherapeutic products.
Where is ImCheck Therapeutics headquartered?
ImCheck Therapeutics is headquartered in Marseille, France.
Which VCs invest in companies like ImCheck Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at ImCheck Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like ImCheck Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.